<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">30 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260925353226/en/U.S.-FDA-Accepts-sNDA-and-Grants-Priority-Review-to-Bayer%E2%80%99s-Lynkuet%C2%AE-elinzanetant-for-a-New-Indication-for-the-Treatment-of-Moderate-to-Severe-Vasomotor-Symptoms-Due-to-Endocrine-Therapy-Related-to-Breast-Cancer/">U.S. FDA Accepts sNDA and Grants Priority Review to Bayer&#39;s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company&#39;s supplemental New Drug Application (sNDA) and granted Priority Review designation for Lynkuet® (elinzanetant) under investigation for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) in women receiving endocrine therapy for trea...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/bayer-sells-cancer-drug-to-gruenenthal-for-up-to-431-million-4e81839b">Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million</a>
    </div>

      <div class="me-0 me-md-5">
        The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260917086669/en/Robigo-and-Leaps-by-Bayer-Announce-Series-A-Financing-to-Advance-Engineered-Biologicals-That-Protect-Yields-and-Reduce-Costs/">Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260916814212/en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-FDA-Approval-as-the-First-New-Treatment-in-30-Years-for-Adults-with-Chronic-Kidney-Disease-CKD-and-Type-1-Diabetes/">Bayer&#39;s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes</a>
    </div>

      <div class="me-0 me-md-5">
        WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with ty...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/government/bayers-monsanto-unit-urges-missouri-judge-approve-725-billion-roundup-settlement-2026-09-14/">Bayer&#39;s Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement</a>
    </div>

      <div class="me-0 me-md-5">
        Bayer&#39;s Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its ​weedkiller Roundup causes cancer, saying there is no other way to resolve the litigation that has weighed on the German ‌company for years.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-faces-pivotal-test-725-billion-roundup-settlement-missouri-court-2026-09-11/">Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court</a>
    </div>

      <div class="me-0 me-md-5">
        Bayer&#39;s Monsanto unit heads to a Missouri state court on Monday seeking ​approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkiller Roundup ‌causes cancer.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260910698539/en/Bayer-Launches-Nationwide-Science-Delivers-Tour-to-Take-Science-on-the-Road/">Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road</a>
    </div>

      <div class="me-0 me-md-5">
        WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the V...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bayer-DE000BAY0017">Bayer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260909948789/en/U.S.-FDA-Grants-Accelerated-Approval-to-Bayer%E2%80%99s-HYRNUO%C2%AE-sevabertinib-as-a-First-Line-Targeted-Therapy-for-Patients-with-HER2-Mutated-Non-Small-Cell-Lung-Cancer/">U.S. FDA Grants Accelerated Approval to Bayer&#39;s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer&#39;s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Bayer-DE000BAY0017/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>